Research Article
Rationales for the Use of Cancer Stem Cells Markers in the Staging of Papillary Thyroid Carcinoma
Table 4
Relationship between cancer stem cells markers expression levels and patient’s clinical features.
| Pathological
data | Patients
Number
39 (%) | ALDH1A1 | CD44 | OCT3/4 | ABCG2 | High
Expression | Low
Expression | High
Expression | Low Expression | High
Expression | Low
Expression | High
Expression | Low
Expression |
| | Age | | | | | | | | | | | ≤ 40 years | 27 (69%) | 24(89%) | 3(11%) | 4(21%) | 23(79%) | 16(59%) | 13(41%) | 22(76%) | 5(34%) | | ≥ 40 years | 12 (31%) | 8(66%) | 4(36%) | 8(67%) | 4(33%) | 5(43%) | 7(57%) | 7(58%) | 5(42%) |
| | P Value | | 0.15 | 0.51 | 0.88 | 0.33 |
| | Gender | | | | | | | | | | | Males | 9 (23%) | 3(33%) | 6(67%) | 5(55%) | 4(45%) | 2(22%) | 7(78%) | 3 (33%) | 6(67%) | | Females | 30 (77%) | 23(77%) | 7(23%) | 22(73%) | 8(37%) | 19(63%) | 11(37%) | 21(70%) | 9(30%) |
| | P Value | | 0.001 | 0.05 | 0.013 | 0.02 |
| | Tumor size | | | | | | | | | | | PT1 | 25(64% ) | 14(56%) | 11(44% ) | 12 (48% ) | 13(52%) | 11(48%) | 14 (52% ) | 15 (60% ) | 10(40%) | | PT2 | 8(20%) | 5(62%) | 3(38%) | 6 (75%) | 2 (25%) | 4(50%) | 4 (50%) | 5 (63%) | 3 (37%) | | PT3 | 6(16%) | 5(83%) | 1(17%) | 6 (100%) | 0 (0.0%) | 4(67%) | 2 (33%) | 5 (83%) | 1(13%) |
| | P Value | | 0.02 | 0.035 | 0.043 | 0.04 |
| | Tumor stage | | | | | | | | | | | Stage I | 25 (64%) | 10 (40%) | 15 (60% ) | 11 (44%) | 14 (56%) | 12(48%) | 13 (52%) | 10 (40%) | 15 60%) | | Stage II | 8 (21%) | 5 (63%) | 3(37%) | 6 (75%) | 2 (25%) | 6(75%) | 2 (25%) | 5 (62%) | 3(38%) | | Stage III | 6 (15%) | 5(83%) | 1 (17%) | 6 (100%) | 0 (0.0%) | 5(83%) | 1 (17% ) | 5 (83% ) | 1(17%) |
| | P Value | | 0.01 | 0.005 | 0.015 | 0.001 |
|
|
